Dave_100
$ESPR checking in every now and then. This quarters sales look to be marginally better than the last. Not a big pickup but just touching double digit QoQ. Still very odd that Otsuka makes absolutely no mention of Nexletol in its quarterly reporting. They have line items for things selling $1M per quarter but this is not broken out or mentioned.
Feeling less and less like I was ripped off by the buyout and maybe this company was just incompetent.
1
8
